Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial

Charles Lawrence Loprinzi, John W. Kugler, Jeff A Sloan, James A. Mailliard, Beth I. LaVasseur, Debra L. Barton, Paul J. Novotny, Shaker R. Dakhil, Kate Rodger, Teresa A. Rummans, Bradley J. Christensen

Research output: Contribution to journalArticle

629 Citations (Scopus)

Abstract

Background: Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Methods: Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks. Findings: 191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg). After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95% CI 11-34), 37% (26-54), 61% (50-68), and 61% (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group. Interpretation: Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.

Original languageEnglish (US)
Pages (from-to)2059-2063
Number of pages5
JournalLancet
Volume356
Issue number9247
DOIs
StatePublished - Dec 16 2000

Fingerprint

Hot Flashes
Survivors
Randomized Controlled Trials
Breast Neoplasms
Placebos
Antidepressive Agents
Therapeutics
Venlafaxine Hydrochloride
Xerostomia
Appetite
Constipation
Drug-Related Side Effects and Adverse Reactions
Nausea
Fear

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., ... Christensen, B. J. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet, 356(9247), 2059-2063. https://doi.org/10.1016/S0140-6736(00)03403-6

Venlafaxine in management of hot flashes in survivors of breast cancer : A randomised controlled trial. / Loprinzi, Charles Lawrence; Kugler, John W.; Sloan, Jeff A; Mailliard, James A.; LaVasseur, Beth I.; Barton, Debra L.; Novotny, Paul J.; Dakhil, Shaker R.; Rodger, Kate; Rummans, Teresa A.; Christensen, Bradley J.

In: Lancet, Vol. 356, No. 9247, 16.12.2000, p. 2059-2063.

Research output: Contribution to journalArticle

Loprinzi, CL, Kugler, JW, Sloan, JA, Mailliard, JA, LaVasseur, BI, Barton, DL, Novotny, PJ, Dakhil, SR, Rodger, K, Rummans, TA & Christensen, BJ 2000, 'Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial', Lancet, vol. 356, no. 9247, pp. 2059-2063. https://doi.org/10.1016/S0140-6736(00)03403-6
Loprinzi, Charles Lawrence ; Kugler, John W. ; Sloan, Jeff A ; Mailliard, James A. ; LaVasseur, Beth I. ; Barton, Debra L. ; Novotny, Paul J. ; Dakhil, Shaker R. ; Rodger, Kate ; Rummans, Teresa A. ; Christensen, Bradley J. / Venlafaxine in management of hot flashes in survivors of breast cancer : A randomised controlled trial. In: Lancet. 2000 ; Vol. 356, No. 9247. pp. 2059-2063.
@article{8b00da6008474f87b3c60de88b847e2f,
title = "Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial",
abstract = "Background: Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Methods: Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks. Findings: 191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg). After week 4 of treatment, median hot flash scores were reduced from baseline by 27{\%} (95{\%} CI 11-34), 37{\%} (26-54), 61{\%} (50-68), and 61{\%} (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group. Interpretation: Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.",
author = "Loprinzi, {Charles Lawrence} and Kugler, {John W.} and Sloan, {Jeff A} and Mailliard, {James A.} and LaVasseur, {Beth I.} and Barton, {Debra L.} and Novotny, {Paul J.} and Dakhil, {Shaker R.} and Kate Rodger and Rummans, {Teresa A.} and Christensen, {Bradley J.}",
year = "2000",
month = "12",
day = "16",
doi = "10.1016/S0140-6736(00)03403-6",
language = "English (US)",
volume = "356",
pages = "2059--2063",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9247",

}

TY - JOUR

T1 - Venlafaxine in management of hot flashes in survivors of breast cancer

T2 - A randomised controlled trial

AU - Loprinzi, Charles Lawrence

AU - Kugler, John W.

AU - Sloan, Jeff A

AU - Mailliard, James A.

AU - LaVasseur, Beth I.

AU - Barton, Debra L.

AU - Novotny, Paul J.

AU - Dakhil, Shaker R.

AU - Rodger, Kate

AU - Rummans, Teresa A.

AU - Christensen, Bradley J.

PY - 2000/12/16

Y1 - 2000/12/16

N2 - Background: Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Methods: Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks. Findings: 191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg). After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95% CI 11-34), 37% (26-54), 61% (50-68), and 61% (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group. Interpretation: Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.

AB - Background: Hot flashes can be troublesome, especially when hormonal therapy is contraindicated. Preliminary data have suggested that newer antidepressants, such as venlafaxine, can diminish hot flashes. We undertook a double-blind, placebo-controlled, randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or reluctance to take hormonal treatment because of fear of breast cancer. Methods: Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or 150 mg daily (n=54). After a baseline assessment week, patients took the study medication for 4 weeks. All venlafaxine treatment started at 37.5 mg daily and gradually increased in the 75 mg and 150 mg groups. Patients completed daily hot-flash questionnaire diaries. The primary endpoint was average daily hot-flash activity (number of flashes and a score combining number and severity). Analyses were based on the women who provided data throughout the baseline and study weeks. Findings: 191 patients had evaluable data for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg). After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95% CI 11-34), 37% (26-54), 61% (50-68), and 61% (48-75) in the four groups. Frequencies of some side-effects (mouth dryness, decreased appetite, nausea, and constipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo group. Interpretation: Venlafaxine is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced against the drug's side-effects. Confirmation of the results of this 4-week study awaits the completion of three ongoing randomised studies to assess the effects of other related antidepressants for the treatment of hot flashes.

UR - http://www.scopus.com/inward/record.url?scp=0034676813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034676813&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)03403-6

DO - 10.1016/S0140-6736(00)03403-6

M3 - Article

C2 - 11145492

AN - SCOPUS:0034676813

VL - 356

SP - 2059

EP - 2063

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9247

ER -